Biotech | February 10, 2022
Gamida Cell initiates rolling submission of Biologics License Application for Omidubicel
On track to complete the BLA submission in the first half of 2022
On track to complete the BLA submission in the first half of 2022
New capabilities on Philips Image Guided therapy mobile C-arm system – Zenition – and collaboration with Cydar offer the latest advances in endovascular treatment
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
The three doses of ZyCoV-D are to be administered 28 days apart. The vaccine was given emergency use authorisation (EUA) by the Indian drug regulator on August 20
This collaborative nursing conference generated a positive dialogue on how the healthcare space of nursing has evolved in the past year
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
A total of 707 district hospitals across all states and union territories participated in the performance assessment. The Health Management Information System (HMIS) data for the year 2017–18 has been used as a baseline for this exercise
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Subscribe To Our Newsletter & Stay Updated
